Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes~* Treated with diet and exercise alone or with metformin for at least 3 months prior to screening~* BMI 27-45 kg/m\^2~* HbA1c between 7.0 % and 8.0 %~Exclusion Criteria:~* Treated with other oral anti-diabetic agents other than metformin within 3 months of screening~* Patients previously treated with AC2993~* Patients presently treated with insulin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo 0.01 mL (Type: PLACEBO_COMPARATOR): 2 week placebo lead-in followed by Placebo 0.01 mL
- Placebo 0.02 mL (Type: PLACEBO_COMPARATOR): 2 week placebo lead-in followed by Placebo 0.02 mL
- Placebo 0.03 mL (Type: PLACEBO_COMPARATOR): 2 week placebo lead-in followed by Placebo 0.03 mL
- Placebo 0.04 mL (Type: PLACEBO_COMPARATOR): 2 week placebo lead-in followed by Placebo 0.04 mL
- AC2993 2.5 mcg (Type: EXPERIMENTAL): 2 week placebo lead-in (0.01 mL) followed by AC2993 2.5 mcg; 0.01 mL
- AC2993 5.0 mcg (Type: EXPERIMENTAL): 2 week placebo lead-in followed by AC2993 5.0 mcg; 0.01 mL
- AC2993 7.5 mcg (Type: EXPERIMENTAL): 2 week placebo lead-in followed by AC2993 7.5 mcg; 0.03 mL
- AC2993 10.0 mcg (Type: EXPERIMENTAL): 2 week placebo lead-in period followed by AC2993 10.0 mcg; 0.04 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).